NASDAQ:PCVX Vaxcyte (PCVX) Stock Price, News & Analysis $63.89 +1.97 (+3.18%) Closing price 11/6/2026 04:00 PM EasternExtended Trading$64.78 +0.89 (+1.40%) As of 11/6/2026 07:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsInsider TradesNews and TrendsOptions ChainOwnershipSEC FilingsShort Interest About Vaxcyte Stock (NASDAQ:PCVX) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Vaxcyte alerts:Sign Up Key Stats Today's Range$61.14▼$65.3050-Day Range$56.05▼$73.8252-Week Range$40.14▼$90.75Volume1.84 million shsAverage Volume3.31 million shsMarket Capitalization$9.51 billionP/E RatioN/ADividend YieldN/APrice Target$110.50Consensus RatingModerate Buy Company Overview Vaxcyte, Inc. (NASDAQ: PCVX) is a clinical-stage biotechnology company focused on developing vaccines designed to protect against serious bacterial diseases. The company is headquartered in San Carlos, California, and uses its proprietary cell-free protein synthesis and conjugation technologies to develop vaccine candidates intended to provide broad and durable immune protection. Vaxcyte’s lead programs target pneumococcal disease, an infection caused by Streptococcus pneumoniae. Its pipeline includes VAX-24, a 24-valent pneumococcal conjugate vaccine candidate, and VAX-31, a broader 31-valent candidate. The company is evaluating these programs for potential use in adults and children. Vaxcyte does not currently have an approved commercial product, and its vaccine candidates remain subject to clinical development and regulatory review. The company was founded in 2013 as SutroVax and adopted the Vaxcyte name in 2020. Its operations and research activities are based primarily in the United States, with clinical development programs conducted across multiple regions as part of international trials. Grant Pickering, Ph.D., serves as Vaxcyte’s chief executive officer.AI Generated. May Contain Errors. Read More Vaxcyte Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks79th Percentile Overall ScorePCVX MarketRank™: 3.960670360855 of 5 starsVaxcyte scored higher than 79% of companies evaluated by MarketBeat, and ranked 103rd out of 886 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion4.3 / 5Analyst RatingModerate Buy Consensus RatingVaxcyte has received a consensus rating of Moderate Buy. The company's average rating score is 2.67, and is based on no strong buy ratings, 7 buy ratings, 1 hold rating, and 1 sell rating.Upside PotentialVaxcyte has a consensus price target of $110.50, representing about 73.0% upside from its current price of $63.89.Amount of Analyst CoverageVaxcyte has been the subject of 7 research reports in the past 90 days, demonstrating strong analyst interest in this stock.Read more about Vaxcyte's stock forecast and price target. Earnings and Valuation0.6 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for Vaxcyte are expected to grow in the coming year, from ($7.47) to ($6.36) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Vaxcyte is -7.93, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Vaxcyte is -7.93, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioVaxcyte has a P/B Ratio of 3.12. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Short Interest4.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted10.16% of the float of Vaxcyte has been sold short.Short Interest Ratio / Days to CoverVaxcyte has a short interest ratio ("days to cover") of 2.89, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Vaxcyte has recently decreased by 15.42%, indicating that investor sentiment is improving significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldVaxcyte does not currently pay a dividend.Dividend GrowthVaxcyte does not have a long track record of dividend growth. News and Social Media3.0 / 5News Sentiment0.73 News SentimentVaxcyte has a news sentiment score of 0.73. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.38 average news sentiment score of Healthcare companies.News Coverage This WeekMarketBeat has tracked 12 news articles for Vaxcyte this week, compared to 4 articles on an average week.Search InterestOnly 7 people have searched for PCVX on MarketBeat in the last 30 days. This is a decrease of -13% compared to the previous 30 days. Company Ownership1.5 / 5Insider TradingSelling Shares Insider Buying vs. Insider SellingIn the past three months, Vaxcyte insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $4,032,875.00 in company stock.Percentage Held by Insiders3.30% of the stock of Vaxcyte is held by insiders.Percentage Held by Institutions96.78% of the stock of Vaxcyte is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Vaxcyte's insider trading history. Receive PCVX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Vaxcyte and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. PCVX Stock News HeadlinesAnalysts Conflicted on These Healthcare Names: Vaxcyte (PCVX), Charles River Labs (CRL) and HCA Healthcare (HCA)November 7 at 1:00 AM | theglobeandmail.comBTIG Sticks to Their Buy Rating for Vaxcyte (PCVX)November 6 at 7:59 PM | theglobeandmail.comBank of America: 'Digital Dollar Inevitable'Bank of America just revealed your expiration date. In their Bloomberg interview, they didn't just predict the digital dollar. They gave us the timeline… 2025 to 2030. We're in that window right now. Once the digital dollar launches, every transaction you make will be tracked. Your spending could be controlled. Your accounts could be frozen. Over 4,500 investors have already used this legal backdoor to hold assets CBDCs can't freeze and generate yields the Federal Reserve can't touch.November 7 at 1:00 AM | Decentralized Masters (Ad)Insider Selling: Vaxcyte (NASDAQ:PCVX) EVP Sells $137,025.00 in StockNovember 5 at 6:37 AM | insidertrades.comVaxcyte Reports Third Quarter 2026 Financial Results and Provides Business UpdateNovember 4 at 4:05 PM | globenewswire.comVaxcyte (PCVX) Expected to Release Earnings on TuesdayNovember 2, 2026 | americanbankingnews.comVaxcyte: Vaccine Titan In The MakingOctober 19, 2026 | seekingalpha.comVaxcyte (NASDAQ:PCVX) EVP Sells $1,561,320.00 in StockOctober 8, 2026 | insidertrades.comSee More Headlines PCVX Stock Analysis - Frequently Asked Questions How have PCVX shares performed this year? Vaxcyte's stock was trading at $46.14 at the beginning of 2026. Since then, PCVX shares have increased by 38.5% and is now trading at $63.89. How were Vaxcyte's earnings last quarter? Vaxcyte, Inc. (NASDAQ:PCVX) released its quarterly earnings data on Wednesday, November, 4th. The company reported ($1.99) EPS for the quarter, topping analysts' consensus estimates of ($2.11) by $0.12. When did Vaxcyte IPO? Vaxcyte (PCVX) raised $234 million in an initial public offering (IPO) on Friday, June 12th 2020. The company issued 15,625,000 shares at a price of $14.00-$16.00 per share. BofA Securities, Jefferies and Evercore ISI acted as the underwriters for the IPO and Cantor and Needham & Company were co-managers. Who are Vaxcyte's major shareholders? Vaxcyte's top institutional investors include Pictet Asset Management Holding SA (0.37%), Candriam S.C.A. (0.30%), Aberdeen Group plc (0.23%) and Russell Investments Group Ltd. (0.10%). Insiders that own company stock include Grant Pickering, Jim Wassil, Andrew Guggenhime, Harpreet S Dhaliwal, Mikhail Eydelman, Elvia Cowan, Teri Loxam, Heath Lukatch and Halley E Gilbert. View institutional ownership trends. How do I buy shares of Vaxcyte? Shares of PCVX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Vaxcyte own? Based on aggregate information from My MarketBeat watchlists, some other companies that Vaxcyte investors own include NVIDIA (NVDA), Viking Therapeutics (VKTX), Taiwan Semiconductor Manufacturing (TSM), Advanced Micro Devices (AMD), Biomea Fusion (BMEA), Definium Therapeutics (DFTX) and Micron Technology (MU). Company Calendar Last Earnings11/04/2026Today11/07/20263rd Annual Guggenheim Healthcare Innovation Conference11/10/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Green Zone (4m+) 1-Year History Nov 25 Feb 26 May 26 Aug 26 Nov 26 PCVX's financial health is in the Green zone, according to TradeSmith. PCVX has been in this zone for over 4 months. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorHealthcare Industry Biotechnology Sub-IndustryBiotechnology Current SymbolNASDAQ:PCVX CIK1649094 Webwww.vaxcyte.com Phone650-837-0111FaxN/AEmployees507Year Founded2013Price Target and Rating Average Price Target for Vaxcyte$110.50 High Price Target$130.00 Low Price Target$77.00 Potential Upside/Downside+73.0%Consensus RatingModerate Buy Rating Score (0-4)2.67 Research Coverage9 Analysts Profitability EPS (Trailing Twelve Months)($8.06) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$766.63 million Net MarginsN/A Pretax MarginN/A Return on Equity-37.56% Return on Assets-33.62% Debt Debt-to-Equity RatioN/A Current Ratio5.72 Quick Ratio5.72 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$20.51 per share Price / Book3.12Miscellaneous Outstanding Shares148,800,000Free Float143,894,000Market Cap$9.51 billion OptionableOptionable Beta1.31 Social Links 10 Best Stocks to Own in Fall 2026AI spending is reshaping the market, and the opportunity extends far beyond the biggest chipmakers. Discover 10 stocks set to benefit from powerful trends in AI infrastructure, cloud computing, energy, capital returns, and consumer growth this fall.Get This Free Report This page (NASDAQ:PCVX) was last updated on 11/6/2026 by MarketBeat.com Staff. From Our PartnersEvery Starlink dish pays this stockThere's a chip inside every Tesla and Starlink dish that Elon doesn't own. He pays royalties to use it. Now...Behind the Markets | SponsoredMy public warning after 55 years of watching the marketsDr. Martin D. Weiss has publicly predicted six major American market crashes over his 55-year career, each war...Weiss Ratings | SponsoredThe investigation Porter spent tens of thousands to documentPorter Stansberry flew the Porter and Co. team 3,300 miles to Dublin to investigate a 17-year investing experi...Porter & Company | SponsoredBank of America: 'Digital Dollar Inevitable'Bank of America just revealed your expiration date. In their Bloomberg interview, they didn't just predict the...Decentralized Masters | SponsoredOne Ticker Tied to a Coming 401k ChangeAn email announcing a new 401k investment option is headed to roughly 70 million inboxes. Most recipients will...Brownstone Research | SponsoredTesla pays $0 in dividends. This new fund paid $452 in one month on $5,000.Tesla has never paid shareholders a dividend, not one cent. A new fund built on Tesla's stock takes a differen...Investors Alley | SponsoredDon't lose access to thisIan Cooper is giving away his guide, The Simple Path To Success With Options, before it moves behind a paywall...TradeWins | SponsoredLast note from me on thisJoel Peterson's free workshop breaks down a three step, three color system that works across stocks, ETFs, gol...The Cycle Code | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Vaxcyte, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Vaxcyte With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
